Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International

Additional urine measurements showed statistically significant placebo-adjusted reductions in albumin and protein loss at four weeks.

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) announced publication of its Phase 2 Explore-CKD trial results for lorundrostat in Kidney International.

The trial randomized 59 participants with uncontrolled hypertension, stage 1 to 3b chronic kidney disease and albuminuria, or albumin loss in urine. Lorundrostat 25 mg once daily, added to an SGLT2 inhibitor, met the primary endpoint at four weeks: automated office systolic blood pressure fell 9.3 mmHg versus 1.8 mmHg with placebo, a 7.5 mmHg placebo-adjusted reduction (p=0.0024). The urinary albumin-to-creatinine ratio, a measure of kidney protein loss, fell 25.6% versus placebo (p=0.0015). Serum aldosterone decreased 41.5% with lorundrostat versus a 1.8% increase with placebo.

The company expects longer-term data shortly from Explore-CKD participants enrolled in the Transform-HTN open-label extension, where treatment is known to participants and investigators.

8 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPrimary endpoint met: four-week systolic pressure fell 9.3 mmHg versus 1.8 mmHg with placebo; placebo-adjusted reduction 7.5 mmHg (p=0.0024).
• Minor pointDiastolic blood pressure fell 3.9 mmHg with lorundrostat versus 1.4 mmHg with placebo.
• Minor pointUrinary albumin-to-creatinine ratio fell 30.5% from baseline and 25.6% placebo-adjusted at four weeks (p=0.0015).
• Minor point24-hour urinary albumin-to-creatinine ratio showed a significant 26.1% placebo-adjusted reduction (p<0.0001).
• Minor point24-hour urine protein-to-creatinine ratio showed a significant 22.1% placebo-adjusted reduction (p=0.0002).

3 minor points

• Minor pointSerum aldosterone decreased 41.5% with lorundrostat versus a 1.8% increase with placebo.
• Minor pointSerum cortisol showed no clinically meaningful changes in either treatment sequence.
• Minor point. Forward-looking: it has not happened yet and may not happen.Longer-term Explore-CKD data from Transform-HTN extension participants are expected shortly, the company said.

Negative

• None.

Argus 15 min delay 1 alert

+4.16% vs previous close $22.01 last price 3.5x rel. volume Open Argus

Details

Market move: MLYS +4.16% vs previous close. Phase 2 Explore-CKD clinical data

$20.64 – $23.78 Day Range

$1.95B Mkt Cap at Last Price

On Oct 28, the day this news came out, the latest delayed price for MLYS is 4.16% above the previous close. The latest delayed price is $22.01. Relative volume is very high at 3.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Trial participants: 59 participants Placebo-adjusted systolic blood pressure reduction: 7.5 mmHg (95% CI: -12.3 to -2.7; p=0.0024) Placebo-adjusted UACR reduction: 25.6% (p=0.0015) +3 more

Trial participants

59 participants

Phase 2 Explore-CKD

Placebo-adjusted systolic blood pressure reduction

7.5 mmHg (95% CI: -12.3 to -2.7; p=0.0024)

Week 4; lorundrostat 25 mg once daily

Placebo-adjusted UACR reduction

25.6% (p=0.0015)

Week 4

24-hour UACR reduction

26.1% (p<0.0001)

Placebo-adjusted

24-hour urine protein-to-creatinine ratio reduction

22.1% (p=0.0002)

Placebo-adjusted

Serum aldosterone change

41.5% decrease

With lorundrostat

Key Terms

sglt2 inhibitor, aldosterone synthase inhibitor, albuminuria, proteinuria, +2 more

6 terms

sglt2 inhibitor medical

"lorundrostat 25 mg once daily added to an SGLT2 inhibitor"

A SGLT2 inhibitor is a type of prescription drug that helps the kidneys remove excess sugar from the blood by blocking a specific transporter, so more glucose leaves the body in urine. Think of it like opening a controlled drain to lower blood sugar. Investors pay attention because clinical benefits, regulatory approvals, safety issues, patent life and competition directly affect sales, pricing and long-term market value for companies in this class.

aldosterone synthase inhibitor medical

"lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy"

Aldosterone synthase inhibitors are drugs that reduce production of the hormone aldosterone, which helps control salt, water balance, and blood pressure. Think of them as turning down a faucet that feeds excess blood pressure and fluid buildup; by lowering aldosterone they can ease strain on the heart and kidneys. Investors track these drugs because trial results, regulatory approval, and safety can materially affect a developer’s revenue outlook and stock value.

albuminuria medical

"additional significant reductions in albuminuria and proteinuria"

Albuminuria is the presence of the blood protein albumin in a person’s urine, which usually indicates the kidneys are leaking and not filtering blood properly. Investors watch it because changes in albuminuria are a common clinical signal used to judge kidney disease progression and treatment effectiveness—similar to spotting oil in a car’s coolant, it flags a malfunction and can affect the market for drugs, diagnostics, and health-related revenue streams.

proteinuria medical

"additional significant reductions in albuminuria and proteinuria"

Proteinuria is when abnormal amounts of protein are found in a person's urine. It can be a sign that the kidneys aren't working properly, since healthy kidneys usually prevent most proteins from passing into urine. Detecting proteinuria helps doctors identify and monitor kidney problems early.

uacr medical

"UACR (urinary albumin-to-creatinine ratio, an indicator of kidney protein loss)"

UACR is a lab measure that compares the amount of albumin (a blood protein) found in urine to the amount of creatinine, and it indicates how much protein is leaking from the kidneys. Investors watch UACR because rising or falling values act like a car’s warning light for kidney damage — changes can show whether a therapy is working or a disease is progressing, which influences clinical trial outcomes, regulatory decisions and company value.

estimated glomerular filtration rate medical

"mean estimated glomerular filtration rate (eGFR) was 43 mL/min/1.73m2"

Estimated glomerular filtration rate (eGFR) is a calculated measure of how well the kidneys are cleaning waste and excess fluid from the blood, based on blood test results and basic patient information. Think of it as a speedometer for kidney function: a lower number means the kidneys are working more slowly. Investors care because eGFR influences drug dosing, trial eligibility, safety profiles, and the size of patient populations for therapies targeting kidney or related diseases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -

- New hormonal and urinary protein data show a 41.5% reduction in serum aldosterone with additional significant reductions in albuminuria and proteinuria -

RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that the full results from the Phase 2 Explore-CKD trial of lorundrostat in participants with uncontrolled hypertension, CKD and albuminuria have been published in Kidney International and are available online.

The Explore-CKD trial evaluated the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, added to guideline-directed background therapy in 59 participants with uncontrolled hypertension, stage 1 to 3b CKD and albuminuria (albumin loss in the urine), an early manifestation of kidney damage.

“Chronic kidney disease and hypertension are pathologically linked, and approximately 76% of patients with both CKD and hypertension have uncontrolled blood pressure despite treatment with multiple antihypertensive medications,” said Matthew R. Weir, MD, Director of the Division of Nephrology at the University of Maryland Medical Center, Professor of Medicine at the University of Maryland School of Medicine, lead author of the publication and scientific consultant for Mineralys. “The Explore-CKD results demonstrate that lorundrostat may help CKD patients reduce otherwise uncontrolled high blood pressure and potentially improve their kidney function.”

"With this publication we have additional peer-reviewed evidence demonstrating the potential benefits of lorundrostat for people living with uncontrolled or resistant hypertension and CKD, a population that is especially difficult to treat," said Terry Ferguson, MD, Chief Medical Officer of Mineralys Therapeutics. "There were consistent reductions in urinary protein loss, along with the expected reductions in serum aldosterone levels. Further evaluation of lorundrostat as a therapeutic approach for lowering blood pressure and reducing albuminuria in participants with CKD will follow shortly, with longer-term data from Explore-CKD participants enrolled in the Transform-HTN open-label extension study.”

Key Findings from Explore-CKD

Explore-CKD randomized 59 participants at 42 sites in the United States. Participants had a mean age of 64.6 years and a mean body mass index of 33.1 kg/m2, and 76% had type 2 diabetes. Of the participants, 30.5% were female, 16.9% were Black or African American and 42.4% were Hispanic or Latino. At baseline, mean automated office systolic blood pressure (AOSBP) was 149 mmHg, UACR (urinary albumin-to-creatinine ratio, an indicator of kidney protein loss) was 516.8 mg/g and mean estimated glomerular filtration rate (eGFR) was 43 mL/min/1.73m2 based on cystatin C. Overall, 64.4% of participants were taking three or more antihypertensive medications.

The primary efficacy endpoint was the change from baseline in systolic blood pressure at week four in the active versus placebo treatment period. At week four, lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in AOSBP, compared with a 1.8 mmHg reduction for placebo, yielding a placebo-adjusted reduction of 7.5 mmHg (95% CI, -12.3 to -2.7; p=0.0024). Automated office diastolic blood pressure was reduced by 3.9 mmHg with lorundrostat and 1.4 mm Hg with placebo.

Lorundrostat also reduced UACR by 30.5% from baseline and by 25.6% placebo-adjusted (p=0.0015) at week four. The placebo-adjusted reductions were also significant for 24-hour UACR (26.1%; p<0.0001) and 24-hour urine protein-to-creatinine ratio (22.1%; p=0.0002).

Serum aldosterone decreased by 41.5% with lorundrostat and increased by 1.8% with placebo, and plasma renin activity rose by 75.2% and 4.2%, respectively. No clinically meaningful changes in serum cortisol were observed in either treatment sequence.

The nature and incidence of adverse events were similar to those in prior lorundrostat trials and consistent with its mechanism of action.

About Explore-CKD

The Explore-CKD trial (NCT06150924) was a randomized, double-blind, placebo-controlled, two-period, two-sequence (2x2) crossover Phase 2 clinical trial. This trial was designed to evaluate blood pressure reduction and safety of 25 mg once-daily lorundrostat when added to background treatment with an ACEi or ARB and an SGLT2 inhibitor for the treatment of hypertension in participants with CKD with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 and albuminuria (UACR of 200-5,000 mg/g). The primary efficacy endpoint of the trial was change from baseline in systolic blood pressure at week four in the active versus placebo treatment period. Exploratory endpoints included change from baseline in UACR and eGFR at week four in the active versus placebo treatment period.

About Chronic Kidney Disease (CKD)

CKD, which is characterized by the gradual loss of kidney function, is estimated to affect more than 10% of the global population and is one of the leading causes of mortality worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 1 in 10 (14%) adults aged 18 or older (approximately 37 million people) are estimated to have CKD. Approximately 21% of adults with high blood pressure are estimated to have CKD. The relationship between these conditions is tightly linked: sustained hypertension may contribute to impaired kidney function, and progressive decrease in kidney function may lead to worsening blood pressure. When CKD is present in patients with hypertension, the risk of cardiovascular disease and mortality rises significantly.

Emerging evidence points to dysregulated aldosterone as a key driver of both diseases. Excess aldosterone promotes sodium retention, vascular inflammation and fibrosis, contributing to both uncontrolled blood pressure and kidney injury. Despite the availability of existing therapies, a significant proportion of patients remain uncontrolled or undertreated. Early detection and targeted interventions that address underlying mechanisms, such as aldosterone dysregulation, may offer the potential to slow CKD progression, reduce cardiovascular risk and improve long-term outcomes. Without effective management, CKD can advance to kidney failure, requiring dialysis or transplantation.

About Hypertension

Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the United States. In 2022, more than 685,000 deaths in the United States included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an estimated annual economic burden of about $219 billion in the United States in 2019.

Less than 50% of hypertensive patients achieve their blood pressure goal with currently available medications. Dysregulated aldosterone levels are a key factor in driving hypertension in approximately 30% of all hypertensive patients.

About Lorundrostat

Lorundrostat is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as related comorbidities, such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.

Mineralys has completed six late-stage clinical trials of lorundrostat supporting its efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN and rHTN. The clinical program includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial, which support the robust, durable and clinically meaningful reductions in systolic blood pressure by lorundrostat. Lorundrostat was well tolerated in both trials with a favorable safety profile.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Forward-Looking Statements

Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on Mineralys’ current beliefs and expectations and include, but are not limited to, statements regarding the potential therapeutic benefits of lorundrostat. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Mineralys’ business, including, without limitation: any delays in the Food and Drug Administration’s (FDA) review of Mineralys’ accepted new drug application (NDA), including as a result of a government shutdown or reductions in agency funding or personnel; the results of Mineralys’ clinical trials, including the Launch-HTN and Advance-HTN trials, may not be deemed sufficient by the FDA to serve as the basis for regulatory approval of lorundrostat; later developments with the FDA may be inconsistent with the feedback from prior meetings, including whether the proposed pivotal program will support registration of lorundrostat following the FDA’s review of Mineralys’ NDA submission; the risk that future funding under the secured debt facility may not be available on the timeframe Mineralys expects, or at all, including as a result of its failure to meet the conditions required for such funding or failure to comply with the affirmative and negative covenants under the debt facility; Mineralys may not be able to reach agreement on the proposed termination of its license agreement with Tanabe on its expected timeframe, or at all; Mineralys’ future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; Mineralys’ dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; macroeconomic trends and uncertainty with regard to high interest rates, elevated inflation, tariffs and other trade policies, and the potential for a local and/or global economic recession; Mineralys’ ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; Mineralys’ reliance on its exclusive license with Tanabe to provide Mineralys with intellectual property rights to develop and commercialize lorundrostat; and other risks described in Mineralys’ filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did Mineralys Therapeutics' Explore-CKD trial meet its primary endpoint?

Explore-CKD met its primary endpoint of change in systolic blood pressure at week four versus placebo. Lorundrostat 25 mg once daily reduced automated office systolic pressure by 9.3 mmHg, compared with 1.8 mmHg for placebo. The placebo-adjusted reduction was 7.5 mmHg, with a 95% confidence interval of -12.3 to -2.7 and p=0.0024.

What kidney protein-loss results did Mineralys report from Explore-CKD?

Lorundrostat reduced the urinary albumin-to-creatinine ratio by 25.6% versus placebo at week four (p=0.0015). Significant placebo-adjusted reductions also occurred in the 24-hour urinary albumin-to-creatinine ratio, at 26.1% (p<0.0001), and the 24-hour urine protein-to-creatinine ratio, at 22.1% (p=0.0002).

What safety findings did Mineralys report for lorundrostat in Explore-CKD?

The nature and incidence of adverse events were similar to prior lorundrostat trials and consistent with its mechanism of action. No clinically meaningful changes in serum cortisol were observed in either treatment sequence.

What were the baseline characteristics of participants in Mineralys' Explore-CKD trial?

Participants had mean automated office systolic blood pressure of 149 mmHg at baseline, and 64.4% were taking three or more blood-pressure medications. Mean estimated glomerular filtration rate, a kidney filtration measure, was 43 mL/min/1.73m2 based on cystatin C. The urinary albumin-to-creatinine ratio was 516.8 mg/g, and 76% had type 2 diabetes.